Although Erk kinase has been recently reported to function in the DNA damage response, the mechanism governing this process is unknown. We report here that hydroxyurea (HU) activates Erk via MEK1, a process that is sensitized by a constitutively active MEK1 (MEK1Q56P) and attenuated by a dominant-negative MEK1 (MEK1K97M). While ectopic MEK1Q56P sensitized HU-induced S-phase arrest, inhibition of Erk activation via U0126, PD98059, and MEK1K97M attenuated the arrest, and thereby enhanced cells to HU-induced toxicity. Taken together, we demonstrate an important contribution of Erk to the activation of the S-phase DNA damage checkpoint. This can be attributed to Erk's regulatory role in modulating ATR function. Inhibition of Erk activation with U0126/PD98059 and MEK1K97M substantially reduced HU-induced ATR nuclear foci, leading to a dramatic reduction of cH2AX and its nuclear foci. Reduction of MEK1 function by a small interference RNA (siRNA) MEK1 and ectopic MEK1K97M significantly decreased HU-induced cH2AX. Conversely, ectopic MEK1Q56P enhanced cH2AX foci. Furthermore, immunofluorescent and cell fractioning experiments revealed cytosolic and nuclear localization of ATR. HU treatment caused the redistribution of ATR from the cytosol to the nucleus, a process that is inhibited by U0126. Collectively, we show that Erk kinase modulates HU-initiated DNA damage response by regulating ATR function.
Introduction
Eukaryotic cells employ multiple mechanisms to ensure accurate transmission of genetic information between generations. Critical surveillance of this transmission is provided by the DNA damage response (Zhou and Elledge, 2000) . Disruption or attenuation of this response plays an essential role in promoting tumorigenesis (Lengauer et al., 1998; Hoeijmakers, 2001; Schar, 2001; Rouse and Jackson, 2002) . Stalled replication forks are sensed by replication protein A (RPA)-mediated ATR (ATM-and Rad3-related kinase) recruitment to DNA damage-induced nuclear foci (Zou and Elledge, 2003) . ATR and its related ATM kinases play central roles in the amplification of double-stranded break (DSB) signals, coordination of DNA damage repair and activation of cell cycle checkpoints (Zhou and Elledge, 2000; Shiloh, 2003) .
One of the first events initiated by DSBs is the phosphorylation of serine 139 in the SQE motif located on the tail of histone H2AX (gH2AX) by ATM/ATR kinases, with subsequent rapid formation of gH2AX foci at the DSB sites (Redon et al., 2002) . These foci are essential in facilitating the assembly of repair factors, including Brca1 and the MRE11-RAD50-NBS1 complex, on damaged DNA (Paull et al., 2000; Celeste et al., 2002) , and also aid in the transduction of DNA damage signals by binding to 53BP1 and MDC1 (FernandezCapetillo et al., 2002; Stewart et al., 2003) . gH2AX foci also form at sites of physiological DSBs in lymphocytes and germ cells (Chen et al., 2000; Mahadevaiah et al., 2001; Petersen et al., 2001; Fernandez-Capetillo et al., 2003) . Knocking out H2AX produces mice with immune deficiency and male infertility , while loss or reduction of H2AX compromises genome stability and facilitates tumorigenesis Bassing et al., 2003; Celeste et al., 2003) . Taken together, gH2AX foci play an essential role in the cellular DNA damage response.
Cell cycle progression is regulated by Erk (extracellular signal regulated) kinase, a member of the mitogen-activated protein kinase family (Kolch, 2000; Johnson and Lapadat, 2002) . Erk is activated by its upstream kinases, MEK1 and MEK2 (Krepinsky et al., 2002) . Activation of Erk is sufficient to transform NIH3T3 cells or mouse embryonic fibroblast (MEF) lacking either p53 or p16 (Cowley et al., 1994; Lin et al., 1998) . However, Erk may also play a role in the cellular DNA damage response, which is a tumour suppression process. Erk activation was observed in response to multiple DNA damage stimuli (Lee et al., 2000; Persons et al., 2000; Wang et al., 2000; Tang et al., 2002; Pippin et al., 2003) in either a p53-dependent (Lee et al., 2000) or independent manner . However, the mechanisms responsible for Erk modulation of the DNA damage response are unknown. While Erk activity facilitates cisplatin-and etoposide-induced apoptosis and cell cycle arrest (Wang et al., 2000; Tang et al., 2002) , it antagonizes C5b-9-induced DNA damage in podocytes (Pippin et al., 2003) .
We report here that Erk kinase contributes to hydroxyurea (HU)-induced S-phase DNA checkpoint activation by regulating ATR function. HU induces Erk activation in several cell lines. Inhibition of Erk activation by specific MEK inhibitors U0126 and PD98059 reduces HU-induced ATR nuclear foci, leading to the reduction of gH2AX nuclear foci. Furthermore, we demonstrate for the first time that a small portion of ATR resides in the cytosol and that HU treatment leads to complete nuclear localization of ATR. Inhibition of Erk activation prevents this ATR redistribution in response to HU. Thus, Erk kinase plays an important role in modulation of the DNA damage response.
Results

HU activates Erk kinase via MEK1
We have previously shown that Erk kinase activity facilitates the etoposide-activated G2/M checkpoint . To investigate whether Erk kinase plays a role in S-phase DNA damage checkpoint regulation, we examined HU-induced S-phase checkpoint activation. HU dose-dependently activates Erk kinase in MCF7 cells (Figure 1a , left panel) as well as in NIH3T3 and mouse embryonic fibroblast (MEF) cells (Figure 1a, right panel) . This process does not require p53 function as HU activates Erk with comparable magnitude in both wild-type and p53 À/À MEFs ( Figure 1a , right panel), an observation consistent with our previous finding of p53-independent Erk activation by etoposide . Since the activation of Erk is mainly mediated by its upstream kinase MEK1, we determined whether MEK1 is involved in HUinduced Erk activation. MCF7 cells were infected with either an empty vector (pBabe) or a constitutively active MEK1 (MEK1Q56P) retrovirus and cultured in puromycin medium for four passages to allow cells to reach a stable condition. This underlies the reason for the comparable basal levels of Erk activity in vector and MEK1Q56P-infected cells (Figure 1b) . Analysis of infected cells in earlier passages showed significantly higher levels of Erk activation in MEK1Q56P cells than in pBabe cells (data not shown). Expression of MEK1Q56P was confirmed by Western blot (data not shown). Compared to pBabe cells, HU produced higher levels of Erk activation in MEK1Q56P cells, which requires higher doses of U0126, the most potent MEK inhibitor (Krepinsky et al., 2002) , to block the Erk activation (Figure 1b) . Conversely, ectopic expression of a dominant-negative mutant MEK1 (MEK1K97M) (Mansour et al., 1994) attenuated HUinduced Erk activation (Figure 1c ). Taken together, these data reveal that MEK1 plays a role in HU-induced Erk activation.
Erk activity facilitates HU-induced S-phase arrest Since HU activates the cellular S-phase checkpoint, we examined whether Erk activity contributes to S-phase checkpoint activation. We treated MCF7 cells with HU in the presence or absence of U0126. While U0126 alone À/À cells were treated with HU at the indicated doses for 6 h. Phosphorylated Erk (Erk-P) and total Erk were examined by Western blot using specific antibodies. The levels of Erk activation in HU-treated cells were standardized against those in untreated cells. (b) MCF7 cells were infected with pBabe or MEK1Q56P retrovirus and selected in puromycin for four passages. Cells were then pretreated with U0126 at the indicated doses for 30 min before addition of HU for 24 h. Total Erk and Erk activation were determined by Western blot. (c) MCF7 cells were infected with an empty vector retrovirus (pLHCX) or MEK1K97M, and cultured in hygromycin-containing medium for four passages. The expression of MEK1K97M was determined (inset). Cells were treated with the indicated doses of HU for 24 h, and analysed for total Erk protein and Erk activation by Western blot using specific antibodies. The levels of HU-induced Erk activation were standardized against those in untreated cells and graphed. The experiment was repeated twice and representative results are shown.
Erk kinase facilitates S-phase DNA damage checkpoint D Wu et al at 50 mM slightly reduced G1-phase progression, an observation consistent with a role of Erk kinase in the facilitation of G1 Cdk activation (Lavoie et al., 1996; Weber et al., 1997; Cheng et al., 1998) , U0126 attenuated HU-induced S-phase arrest in MCF7, MEF, NIH3T3, and HCT116 cells (Table 1) . Another MEK inhibitor, PD98059, essentially produced the same results (data not shown), suggesting a general role for Erk in DNA damage-induced S-phase checkpoint activation. Consistent with the observation that U0126 at 10 mM inhibited HU-induced Erk activation in MCF7/pBabe but not MCF7/MEK1Q56P cells (Figure 1b ), U0126 at 10 mM affected HU-induced S-phase arrest much more dramatically in MCF7/pBabe than in MCF7/MEK1Q56P cells ( Figure 2A ). This result further supports a facilitating function of Erk kinase in S-phase checkpoint activation. As Erk activity facilitates G1-phase progression (Cheng et al., 1998) , inhibition of Erk activation by U0126 may lead to G1-phase arrest, and thus reduces the magnitude of HU-induced S-phase arrest as a consequence of the inability of cells to enter S phase. However, this possibility is very unlikely, since (1) Ctrl: mock (DMSO) treated; U: U0126 (50 mM); HU: hydroxyurea (1 mM for MCF7 and HCT116, 0.3 mM for MEF and NIH3T3). Cells were pretreated with U0126 for 30 min and were then subjected to HU for 24 h. Figure 2A ). This indicates that the delayed S-phase entry associated with U0126 is not the predominant event that reduces HU-induced S-phase arrest by preventing cells entry into S phase.
To further exclude such a possibility, S-phase progression in response to HU with or without U0126 was determined. MCF7 cells were briefly pulsed with 5 0 -bromo-2-deoxyuridine (BrdU) for 30 min to label the S-phase cells (Figure 2Ba ). A 24-h chase resulted in progression of the majority of BrdU-positive cells into G1 (Figure 2Bb , red BrdU-positive population), which was not obviously affected by U0126 at 50 mM ( Figure  2Bc ). As expected, HU prevented S-phase progression ( Figure 2Bd ). Addition of U0126 partially released the S-phase arrest, as cells advanced further into S phase with U0126 ( Figure 2Be ) than those without ( Figure 2Bd ). Similar results were also obtained in NIH3T3 cells (data not shown). Taken together, these data show that Erk activity facilitates HU-induced S-phase arrest.
Inhibition of Erk activity sensitizes cells to HU toxicity
Disruption of DNA damage checkpoints, such as those caused by mutations in ATM, NBS (Nijmegen breakage syndrome), and MRE11, sensitizes cells to genotoxic stresses (Shiloh, 1997; Stewart et al., 1999) . To determine whether inhibition of Erk activation enhances cells to HU-mediated toxicity, NIH3T3 cells were treated with HU at 100 mM with or without U0126 (50 mM) for 12 h and then were released into normal medium for approximately 2 weeks. No obvious apoptosis could be detected during the 12-h treatment (data not shown). Inhibition of Erk activation dramatically compromised the survival capacity of the cells to HU (Figure 3a ). U0126 alone for 12 h did not reduce the survival ability and the proliferation rate of the cells compared to those of mock-(DMSO) treated cells ( Figure 3a ). To examine whether U0126-mediated toxicity sensitization is specific to HU-induced DNA damage, we also treated NIH3T3 cells with etoposide for 8 h and with UV under subapoptotic doses, in the absence and presence of U0126. Again, cells treated with U0126 were hypersensitive to the cytotoxic action of etoposide and UV (data not shown), supporting a general role of Erk kinase in the cellular DNA damage response. Furthermore, similar results were also obtained from MCF7 cells. We have predetermined the density of MCF7 cells to produce approximately 30-40 colonies in six-well plates and found that 24 h-treatment of MCF7 cells with HU from 0.05 to 1 mM for 24 h was not apoptotic (data not shown). Using these conditions, we were able to show that inhibition of Erk activation sensitized MCF7 cells to HU toxicity starting from 0.1 mM onward (Figure 3b ). To confirm that the U0126 effect observed above was due to its inhibition on MEK1, we examined whether a dominant-negative MEK1 (MEK1K97M) also sensitizes cells to HUinduced toxicity. While MCF7/MEK1K97M cells proliferated and survived at a comparable rate as MCF7/ pLHCX (an empty vector) cells (Figure 3c , see the control (Ctrl) cells), HU treatment further compromised Figure 3 Inhibition of Erk activation sensitizes cells to HUassociated toxicity. (a) NIH3T3 cells seeded into six-well plates to 50% confluence were treated for 12 h with DMSO or U0126 (50 mM) or U0126 plus HU (0.1 mM). The cells were subsequently cultured in normal medium until colonies formed (approximately 2-3 weeks), which were stained with 0.1% crystal violet. The cells treated with DMSO and U0126 were confluent in 2 days, and were subsequently stained with crystal violet. (b) MCF7 cells (500-1000 cells) were seeded into six-well plates in triplicates for 24 h before treated with the indicated doses of HU in the presence or absence of U0126 (50 mM) for 24 h. Cells were then released into normal culture medium for approximately 2 weeks until colonies formed. The experiments were repeated at least three times. Asterisks (**) represent statistical significance (Po0.01, small t-test). (c) MCF7/ pLHCX (vector) and MCF7/MEK1K97M cells were seeded into six-well plates, treated with HU, and stained for surviving cells as described above.
Erk kinase facilitates S-phase DNA damage checkpoint D Wu et al MEK1K97M cell survival when compared to pLHCX cells (comparing the sizes of pLHCX-surviving cell colonies to the sizes of MEK1K97M-surviving cell colonies upon HU treatment) (Figure 3c ). The decreased potency of MEK1K97M compared to U0126 in the sensitization of MCF7 cells to HU toxicity may be due to the observation that U0126 inhibits Erk activation more efficiently than ectopic expression of MEK1K97M (data not shown). Taken together, these results support the concept that the MEK1-Erk pathway functionally contributes to S-phase checkpoint activation in response to HU treatment.
Erk activity regulates ATR function in response to HU To examine the possible mechanism responsible for Erk function in S-phase checkpoint activation, we determined HU-induced p53 serine 15 (p53Ser15) phosphorylation and p21 CIP1 upregulation. NIH3T3 cells were treated with HU with or without U0126 for a 24-h time course before analyzing for p53Ser15 phosphorylation, p53 stabilization, and p21 CIP1 upregulation. While U0126 had no effect on HU-induced p53Ser15 phosphorylation and p53 stabilization in the early phase (up to 4 h), it attenuated these events after 8 h of HU treatment. Kinetically, this matches the profile of HUinduced Erk activation (Figure 4a, top panel) . U0126 consistently decreased HU-induced p21 CIP1 upregulation (Figure 4a, top panel) . As p53 stabilization and p21 CIP1 upregulation contribute to the DNA damage response, the attenuation of these events by U0126 thus supports the notion that Erk functions in S-phase checkpoint regulation. Similar results were also obtained in MCF7 cells (Figure 4a , bottom panel), consistent with U0126 attenuating HU-induced S-phase arrest in both MCF7 and NIH3T3 cells (Table 1) . Taken together, the above results reveal that Erk kinase activity functionally contributes to HU-initiated S-phase checkpoint activation.
Phosphorylation of p53Ser15 is mediated by ATM and ATR in the DNA damage response, and ATR plays an essential role in HU-induced DNA damage response. The fact that U0126 reduces p53Ser15 phosphorylation indicates that Erk kinase may facilitate HU-induced ATR function. To test this hypothesis, we first examined whether ATR kinase activity is modulated by Erk kinase. FLAG-tagged ATR was expressed in 293T cells, and immunoprecipitated for an in vitro kinase assay using recombinant GST-p53 (1-40) as a substrate. While caffeine, as expected, inhibited ATR kinase activity, U0126 exhibited no effects on ATR kinase activity (Figure 4b ). This is in accordance with the theme of ATR activation, in that DNA damage does not affect ATR kinase activity but induces ATR nuclear foci. Formation of ATR nuclear foci in response to DNA damage contributes to ATR function (Tibbetts et al., 2000) .
To determine whether Erk activity regulates ATR nuclear foci, MCF7 cells were treated with 1 mM HU with or without 50 mM U0126 for 24 h. Consistent with a previous report (Tibbetts et al., 2000) , HU induced nuclear ATR foci (Figure 4c) . Interestingly, U0126 substantially reduced the magnitude of these foci (Figure 4c ). Consistent with both U0126 and PD98059 being among the most specific protein kinase inhibitors, PD98059 produced essentially the same results as those obtained using U0126 (data not shown). The same phenomenon was also observed in NIH3T3 cells (data not shown). To exclude the possibility that U0126-mediated reduction of ATR nuclear foci was due to possible nonspecific actions instead of its inhibition of Erk activation, we showed that a large portion of ATR localizes in the perinuclear region in untreated (control) vector cells, while enforced activation of Erk via ectopic expression of a constitutively active MEK1Q56P results in the redistribution of ATR throughout the nucleus (Figure 6c) . Furthermore, HU induces extensive ATR nuclear foci in MEK1Q56P cells (Figure 6c ). While HU induces ATR nuclear foci in vector cells, a significant amount of ATR still resides in the perinuclear region in the MEK1K197M cells upon HU treatment, which resembles what was observed in untreated vector cells (Figure 6c ). Downregulation of MEK1 via small interference RNA (siRNA) also reduced HU-induced ATR nuclear foci (data not shown). By counting approximately 200 nuclei, we further demonstrated that ectopic expression of MEK1Q56P and MEK1K97M sensitizes and attenuates ATR nuclear focus formation, respectively, in a HU-dose-dependent manner (Figure 6d ). Taken together, the above results demonstrate that activities modulating Erk activation plays a role in HU-induced formation of ATR nuclear foci.
Erk activity plays a role in HU-induced formation of gH2AX nuclear foci H2AX is phosphorylated by ATR on Ser139 (gH2AX) in response to HU (Ward and Chen, 2001 ). Nuclear gH2AX foci are formed on DNA DSBs and function in recruiting DNA repair factors , suggesting that HU-induced production of gH2AX is facilitated by Erk kinase activity. To test this possibility, MCF7 and NIH3T3 cells were treated with HU with or without U0126 for 24 h before Western blot analysis for gH2AX. While HU treatment led to the production of gH2AX, U0126 reduced the levels of gH2AX in MCF7 and NIH3T3 cells in a dose-dependent manner (Figure 5a ). PD98059 produced the same results in both cell lines (data not shown). Since gH2AX is recruited onto DNA breaks and functions in DNA damage repair (Zhou and Elledge, 2000) , we have examined whether inhibition of Erk activation would affect HU-induced gH2AX nuclear foci. Indeed, both U0126 and PD98059 (data not shown) significantly attenuated HU-induced gH2AX nuclear foci in MCF7 (Figure 5b ) and NIH3T3 cells (data not shown).
To consolidate the notion that Erk activity promotes the formation of gH2AX nuclear foci due to HU treatment, we examined whether elevated levels of Erk activation results in enhanced HU-induced gH2AX nuclear foci. MCF7/pBabe and MCF7/MEK1Q56P cells were treated with increasing doses of HU to determine the magnitude of gH2AX nuclear focus Erk kinase facilitates S-phase DNA damage checkpoint D Wu et al formation. It was found that HU induced more gH2AX nuclear foci in MCF7/MEK1Q56P cells than in MCF7/ pBabe cells (Figure 6a) . Furthermore, the foci in MCF7/ MEK1Q56P cells were more sensitive to U0126 than those in MCF7/pBabe cells (Figure 6b ). Collectively, these results support a role for Erk kinase in the formation of HU-induced gH2AX nuclear foci.
To further consolidate this conclusion, we examined HU-induced Erk activation and gH2AX production in MCF7 cells expressing an empty vector (pLHCX) or MEK1K97M
(a dominant-negative MEK1).
MEK1K97M reduced HU-induced Erk activation and gH2AX production ( Figure 7a ) and gH2AX nuclear foci (comparing HU-induced ATR foci in vector and MEK1K97M cells) (Figure 6c ). Conversely, ectopic MEK1Q56P enhanced the basal level of gH2AX nuclear foci (Figure 6c ). Kinetically, ectopic expression of MEK1Q56P and MEK1K97M increased and reduced HU-induced gH2AX nuclear foci, respectively (Figure 6e ). Furthermore, reduction of MEK1 using a specific small interference RNA (siRNA) substantially decreased HU-induced Erk activation and gH2AX Phosphorylated Erk (Erk-P), total Erk, S15 phosphorylated p53 (S15-P), total p53, and p21 CIP1 (p21) were examined by Western blot using specific antibodies (top panel). MCF7 cells were either untreated (control: Ctrl) or treated with U0126 (50 mM) and HU as indicated for 24 h (bottom panel) and phosphorylation of p53Ser15 was determined by immunofluorescence (red). Phase contrast (DIC) and immunofluorescence images were taken using a fluorescent microscope (Zeiss). (b) FLAG-tagged ATR was transiently expressed in 293T cells, immunoprecipitated with an anti-FLAG antibody (M2), and assayed for its kinase activity by phosphorylating GST-p53 in vitro in the absence or presence of U0126 or caffeine. The immunoprecipitated ATR, phosphorylation on S15 of p53 (S15-P) and total GST-p53 were examined by Western blot using specific antibodies for ATR, S15 phosphorylated p53, and GST-p53 (DO-1), respectively (top panel). ATR kinase activity in the presence of U0126 or caffeine was standardized against that of control (bottom panel). Asterisks (**) represent statistical significance (Po0.01, small t-test). (c) MCF7 cells were treated with U0126 and HU as indicated for 24 h and examined for ATR foci by immunofluorescent staining (red). Nuclei were counterstained with DAPI (blue).
Erk kinase facilitates S-phase DNA damage checkpoint D Wu et al ( Figure 7b ). This effect may be specific for MEK1, as reduction of MEK2 by 50% via a siRNAMEK2 had no effect on HU-induced gH2AX (data not shown). The basal levels of Erk activation in MEK1 or MEK2 siRNA-treated cells were comparable with those in control siRNA-treated MCF7 cells (data not shown), an observation consistent with what observed in pLHCX (vector) and MEK1K97M cells (Figure 7a ). Taken together, these data reveal an important role of Erk kinase in the formation of gH2AX nuclear foci in response to HU. This further supports the conclusion that Erk kinase functions in the regulation of ATR function in HU-initiated DNA damage response.
Erk kinase facilitates HU-induced ATR redistribution from the cytosol to the nucleus The central mechanism responsible for executing ATR function upon DNA damage is the redistribution of ATR into nuclear foci. The observation that Erk kinase facilitates ATR foci formation in response to HU suggests that Erk kinase plays a role in this ATR redistribution. Although ATR was reported as being a nuclear protein, we have repeatedly detected its cytosolic localization in MCF7 cells (Figure 4c ) by using two commercially available anti-ATR antibodies. To confirm this observation, we have fractioned MCF7 cells. Although ATR was predominantly localized in the nucleus, we also detected it in the cytosol in a ratio of approximately 1:4 (cytosol:nucleus) (Figure 8b , control cells). The observation of the cytosolic localization of ATR prompted us to hypothesize that Erk kinase may facilitate HU-induced redistribution of ATR from the cytosol to the nucleus. To test this hypothesis, we examined a time course of HU-induced ATR nuclear foci formation. In MCF7 cells, ATR started to form detectable nuclear foci 12 h after a HU challenge, and was largely redistributed into nuclear foci after 24 h (Figure 8a ). Again, cytosolic distribution of ATR was also observed (Figure 8a ). We then treated MCF7 cells with HU in the absence or presence of U0126 for 24 h, followed by the separation of cells into cytosolic and nuclear fractions. While MEK2 and laminin B localized in the cytosol and nucleus, respectively, as expected (Figure 8b ), approximately 20-30% of ATR remained in the cytosol in untreated MCF7 cells. HU treatment Erk kinase facilitates S-phase DNA damage checkpoint D Wu et al completely translocated the cytosolic ATR into the nucleus (Figure 8b ). In the presence of U0126 (Figure 8b ) or PD98059 (data not shown), HU was incapable of inducing this ATR mobilization. Furthermore, U0126 also increased the basal level of cytosolic ATR (Figure 8b , comparing the relative amounts of cytosolic versus nuclear ATR in control and U0126-treated cells). Collectively, these observations indicate that Erk kinase activity may promote the trafficking of ATR from the cytosol to the nucleus in response to HU.
Discussion
It is a growing concept that DNA damage checkpoints, now reframed as the DNA damage response, play an essential role in maintaining genome integrity. This Figure 6 Erk activity contributes to HU-induced gH2AX nuclear foci. (a) MCF7/pBabe and MCF7/MEK1Q56P cells were treated with HU at the indicated doses for 24 h. gH2AX nuclear foci were detected by immunofluorescent staining. At least 200 nuclei in four randomly selected fields were counted and nuclei positive for gH2AX nuclear foci were analysed. Only nuclei with more than 10 foci were regarded as being positive. (b) MCF7/pBabe and MCF7/MEK1Q56P cells were treated with HU (1 mM) and U0126 at the indicated doses for 24 h. The nuclei positive for gH2AX nuclear foci were quantified. (c) Vector, MEK1Q56P, MEK1K97M cells were either mock treated (Ctrl) or HU (1 mM)-treated for 24 h and immunofluorescently stained for ATR (red) and gH2AX (green). Nuclei were stained with DAPI (blue). (d and e) Vector, MEK1Q56P, MEK1K97M cells were treated with HU at the indicated doses for 24 h. ATR and gH2AX nuclear foci were detected by immunofluorescent staining. At least 200 nuclei in four randomly selected fields were counted and nuclei positive for ATR and gH2AX nuclear foci were analysed.
Erk kinase facilitates S-phase DNA damage checkpoint D Wu et al system not only functions in the repair of DNA damage, but also integrates with other cellular processes to regulate cell cycle progression, apoptosis, and transcription (Zhou and Elledge, 2000) . Consistent with its involvement in all of these cellular processes, Erk has been reported by several groups, including ours, to function in the DNA damage response (Lee et al., 2000; Persons et al., 2000; Wang et al., 2000; Tang et al., 2002; Pippin et al., 2003) . However, the mechanism underlying this novel Erk function has not been thoroughly investigated.
We have provided evidence that MEK1 plays a major role in HU-induced Erk activation. This is consistent with the general role of MEK1, but not MEK2, in Erk activation under a variety of conditions (Krepinsky et al., 2002) . While a dominant-negative mutant MEK1 (MEK1K97M) reduces HU-induced Erk activation, a constitutively activated MEK1 (MEK1Q56P) enhances Erk activation (Figure 1) . Expression of MEK1Q56P also enhanced HU-induced S-phase arrest in MCF7 ( Figure 2A ) and NIH3T3 cells (data not shown). Since the major function of MEK1 is to activate Erk, our observations support the concept that MEK1-Erk kinases contribute to HU-induced DNA damage response.
MEK1-Erk activity functionally contributes to HUinduced S-phase checkpoint activation. Modulation of Erk activation via MEK1 influences the S-phase arrest in response to HU treatment. Furthermore, inhibition of Erk activation by U0126 and PD98059 (data not shown) sensitizes cells to HU toxicity. As cells were treated with subapoptotic doses of HU, this sensitization of HU toxicity is most likely attributable to a cellular catastrophe that is caused by DNA damage when checkpoint function is compromised. Our observation is similar to the enhanced toxicity of AT cells (cells without ATM function or with compromised ATM function) to genotoxic stresses (Shiloh, 1997; Stewart et al., 1999) . This catastrophe is caused by the continuation of cellular processes in the presence of DNA damage. AT cells continue to synthesize DNA when exposed to ionizing radiation (Shiloh, 1997) and treated with radiomimetic antibiotics, neocarzinostatin and blemycin (Lehmann and Stevens, 1979 ; Taylor Erk kinase facilitates S-phase DNA damage checkpoint D Wu et al Shiloh et al., 1982) . A similar situation was also observed for MCF7 cells treated with HU in the presence of U0126, in that these cells progressed further into S phase than the cells treated with HU alone ( Figure 2B ). HU causes depletion of dNTP pools by inhibiting ribonucleotide reductase (Atkin et al., 1973; Johns and Gao, 1998) , and thereby activates the S-phase checkpoints. HU was commonly used at 2 mM to achieve a high degree of DNA synthesis inhibition. To investigate the function of S-phase checkpoint activation in HU-mediated S-phase arrest, we intentionally used suboptimal HU doses to avoid complete DNA synthesis inhibition. At the highest dose used (1 mM (Stewart et al., 1999; Falck et al., 2002) . Interestingly, addition of U0126 to HU-treated cells increased DNA synthesis by 15-20% (data not shown). Taken together, we provide compelling evidence that MEK1-Erk functionally contributes to HU-activated S-phase checkpoint activation.
Mechanistically, this is mediated by modulating ATR function. U0126 and PD98059, which are MEK1 and MEK2 inhibitors, effectively block HU-induced ATR nuclear foci. Both inhibitors are well characterized and are among the most specific protein kinase inhibitors (Favata et al., 1998; Davies et al., 2000) . U0126 at 50 mM is widely used to prevent Erk activation in vivo without toxic effects on cells (Ahn et al., 2001) . In a panel of more than 29 kinases tested, U0126 has little effect on kinases (including those of the most closely related MKK3, MKK4, MKK6, and MKK7) other than MEK1 and MEK2 (Favata et al., 1998; Davies et al., 2000) . We show here that these inhibitors also block the downstream events of ATR in response to HU. HUinduced generation of gH2AX and its nuclear foci were substantially reduced by U0126 (Figures 5 and 6 ). Inhibition of MEK1 by ectopic expression of MEK1K97M or using a siRNAMEK1 also led to the reduction of HU-induced gH2AX (Figure 7) , while enhancing MEK1 activation using MEK1Q56P-promoted gH2AX nuclear foci upon HU exposure ( Figure 6 ). These results provide additional support for Erk-mediated ATR function.
Furthermore, we show that Erk facilitates HUinduced ATR nuclear foci by promoting, at least in part, the redistribution of ATR from the cytosol to the nucleus upon HU treatment. Our finding that some ATR is also localized in the cytosol is intriguing, as it is generally believed that ATR is a nuclear protein (Tibbetts et al., 2000) . However, our findings were not artifacts, as (1) we have used two specific anti-ATR antibodies, (2) both immunofluorescent as well as cell fractioning experiments confirmed ATR cytosolic localization, (3) the cytosolic localization of ATR was observed in MCF7 (Figures 4c and 8 ) and NIH3T3 cells (data not shown), and (4) HU exposure abolished the presence of ATR in the cytosol (Figure 8b ). Our finding of the cytosolic localization of ATR is consistent with the cytosolic and nuclear localization of ATM (Yang and Kastan, 2000) , as ATR and ATM are regarded as functional equivalents in mediating a variety of DNA damage responses (Zhou and Elledge, 2000) .
How MEK1-Erk regulates ATR trafficking in the DNA damage response is not clear. Erk may directly phosphorylate ATR, resulting in ATR translocation from the cytosol into the nucleus. Erk may also phosphorylate other factors, which subsequently promote this ATR movement. However, these two mechanisms are not mutually exclusive. Regardless of the possible mechanisms, our data reveal an interesting aspect of Erk function, especially considering the very upstream nature of ATR function in regulating the DNA damage response.
Materials and methods
Materials, cell lines, plasmids, and cell cycle determination Propidium iodide (PI) and HU were purchased from Sigma. MEK1 inhibitors U0126 and PD98059 were purchased from Promega and Calbiochem, respectively. U0126 and PD98059 were prepared in DMSO and used at the concentrations indicated.
NIH3T3 and MCF7 cells were cultured in DMEM supplemented with 10% fetal calf serum (Gibco BRL) at 371C in a tissue culture incubator. MEF and MEF/p53 À/À were gifts from Dr Tak Mak and cultured in DMEM, 10% FCS, 55 mM b-mercaptoethanol and 10 mg/ml gentamycin. IMR-90 was purchased from ATCC and cultured in MEM and 10% FCS. The AT fibroblast line, GM05823, was purchased from NIGMS Human Genetic Cell Repository and cultured in MEM, 10% FCS, with 2 Â concentrated essential and nonessential amino acids and vitamins.
The constitutively activated MEK1Q56P cloned in the retroviral vector, pBabe, was kindly provided by Dr Scott Lowe of Cold Spring Harbor Laboratories. The dominantnegative MEK1 (MEK1K97M) was kindly provided by Dr Natalie G Ahn of University of Colorado. We have subsequently subcloned MEK1K97M into a retroviral vector pLHCX. Cell cycle determination was carried out by PI staining following our published procedure .
Retroviral infection
Retroviral infection was performed following our previously published procedure (Tang et al., 2001; Li et al., 2004) . Briefly, a gag-pol-expressing vector and an envelope-expressing vector (VSV-G) (Stratagene) were transiently cotransfected with a designed retroviral plasmid into 293T cells. After 48 h, the virus-containing medium was harvested, filtered through a 0.45 mM filter, and centrifuged at 50 000 g for 90 min to concentrate the retrovirus. Following the addition of 10 mg/ ml of polybrene (Sigma), the medium was used to infect cells. Infection was selected in puromycin (1 mg/ml).
Cell lysis and Western blot
After exposure to the DNA damage agents as indicated, cells were lysed in a buffer containing 20 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 25 mM sodium pyrophosphate, 1 mM NaF, 1 mM b-glycerophosphate, 0.1 mM sodium orthovanadate, 1 mM PMSF, 2 mg/ml leupeptin and 10 mg/ml aprotinin. In all, 50 mg of total cell lysate was separated on SDS-PAGE gel and transferred onto Immobilon-P membranes (Millipore). Membranes were blocked with 5% skim milk and then incubated with the indicated antibodies at room temperature for 1 h. Signals were detected
